Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

ClinicalTrials.gov ID: NCT01844856

Public ClinicalTrials.gov record NCT01844856. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in the treatment of adult complicated intra-abdominal infections (cIAI).

Study identification

NCT ID
NCT01844856
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Enrollment
541 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2013 (Type not available)
Primary completion
Aug 2014 (Actual)
Completion
Aug 2014 (Actual)
Last update posted
Jan 11, 2022

2013 – 2014

United States locations

U.S. sites
19
U.S. states
11
U.S. cities
19
Facility City State ZIP Site status
Not listed Florence Alabama — —
Not listed Mobile Alabama — —
Not listed Glendale California — —
Not listed La Mesa California — —
Not listed Los Angeles California — —
Not listed Torrance California — —
Not listed Aurora Illinois — —
Not listed Carmel Indiana — —
Not listed Boston Massachusetts — —
Not listed Springfield Massachusetts — —
Not listed Minneapolis Minnesota — —
Not listed Las Vegas Nevada — —
Not listed Camden New Jersey — —
Not listed Teaneck New Jersey — —
Not listed Cleveland Ohio — —
Not listed Columbus Ohio — —
Not listed Weston Ohio — —
Not listed Houston Texas — —
Not listed Seattle Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01844856, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 11, 2022 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01844856 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →